Rate of suicide in patients taking montelukast

Pharmacotherapy

Volumn 29, Issue 2, 2009, Pages 165-166

  Jick, Hershel ^a   Hagberg, Katrina Wilcox ^a   Egger, Pascal ^a,b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Montelukast; Singulair; Suicide

Indexed keywords

ANTIASTHMATIC AGENT; MONTELUKAST;

ARTICLE; ASTHMA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PRESCRIPTION; RISK FACTOR; SUICIDE; TREATMENT DURATION;

ACETATES; ANTI-ASTHMATIC AGENTS; COHORT STUDIES; DATABASES, FACTUAL; FEMALE; GREAT BRITAIN; HUMANS; MIDDLE AGED; QUINOLINES; RISK; SUICIDE;

EID: 59949100656     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.29.2.165     Document Type: Article

References (4)

1. U. S. Food and Drug Administration. Early communication about an ongoing safety review of montelukast (Singulair), March 2008. Available from http://www.fda.gov/cder/drug/earlycomm/montelukast.htm. Accessed April 25, 2008.
2. Derby LE, Jick H, Dean AD. Antidepressant drugs and suicide. J Clin Psychopharmacol 1992;12;235-40.
3. McClure GMG. Changes in suicide in England and Wales, 1960-1997. Br J Psychiatry 2000;176: 64-7.
4. Jick SS, Dean AD, Jick H. Antidepressants and suicide. BMJ 1995;310: 215-18.